Direct Admission to PCI Center Reduces Mortality in STEMI

Share this content:
Direct Admission to PCI Center Reduces Mortality in STEMI
Direct Admission to PCI Center Reduces Mortality in STEMI

THURSDAY, Feb. 16, 2017 (HealthDay News) -- For patients with ST-segment elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI), direct admission to a primary PCI center is associated with lower 12-month mortality, according to a study published online Feb. 15 in JACC: Cardiovascular Interventions.

Using data from a prospective nationwide registry, Damian Kawecki, M.D., Ph.D., from the Medical University of Silesia in Poland, and colleagues examined the impact of direct admission versus transfer via regional hospital to a PCI center on time delays and 12-month mortality in STEMI patients. A total of 70,093 patients were eligible for analysis, of whom 56 percent were admitted directly to a PCI center.

The researchers found that direct admission correlated with a 44-minute shorter median symptoms-to-admission time (P < 0.001) and total ischemic time (228 versus 270 minutes; P < 0.001), higher left ventricle ejection fraction (47.5 versus 46.3 percent; P < 0.001), and lower propensity-matched 12-month mortality (9.6 versus 10.4 percent; P < 0.001). Direct admissions and shorter symptoms-to-admission time were significant predictors of lower 12-month mortality in propensity matched analysis (hazard ratios, 1.06 and 1.03, respectively).

"In a large, community-based cohort of patients with STEMI treated by PCI, direct admission to a primary PCI center was associated with lower 12-month mortality and should be preferred to transfer via a regional non-PCI-capable facility," the authors write.

Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »